Literature DB >> 30157327

IMMUNOPROTECTION OF SOLUBLE EGG ANTIGENS AND PRAZIQUANTEL IN CHALLENGED MURINE SCHISTOSOMIASIS MANSONI.

Naglaa F Abd El-Aal, Faten A Mohammed, Mona Magdy.   

Abstract

Control of schistosomiasis would be greatly improved by the development of a vaccine, which could be combined with chemotherapy. The current study evaluated the potential effect of soluble egg antigens (SEA) associated with or without PZQ in Schistosoma mansoni challenged mice through parasitological, histopathological and serological studies. Sixty Swiss albino fe- male mice divided into 5 groups (12 mice each); each group was subdivided into 2 groups (6 mice each) according initial and challenged infections. Mice were sacrificed by rapid decapita- tion 8 weeks post initial and challenge infections for assessment. The current results showed marked reduction of egg counts per gram stool, worm burden, granuloma number and size in combined SEA and PZQ group. Also, significant increase in serum IL-12 & INF-,y, plus marked decrease in serum IL-4 during initial and challenged infections. The role of PZQ alone was mainly during primary infection and had no role in reinfection, whereas, SEA alone was effec- tive during challenged one. In conclusion, from the obtained results of the current study the combination of SEA & PZQ was as a possible potent and promising prophylactic treatment for schistosomiasis especially during re-infectiob in endemic areas. This prophylactic effect was significantly greater than those observed in the single drug treatment or vaccine used.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 30157327

Source DB:  PubMed          Journal:  J Egypt Soc Parasitol        ISSN: 1110-0583


  1 in total

Review 1.  Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings.

Authors:  Emmanuella Driciru; Jan Pieter R Koopman; Stephen Cose; Afzal A Siddiqui; Maria Yazdanbakhsh; Alison M Elliott; Meta Roestenberg
Journal:  Front Immunol       Date:  2021-03-04       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.